Skip to main content
. 2021 Dec 3;13(23):6107. doi: 10.3390/cancers13236107

Figure 3.

Figure 3

Improved efficacy and increase in multiple antigen-specific CD8+ T cells in the periphery of heterologous prime-boost-treated MC-38 tumor-bearing C57BL/6 mice. (A) Treatment schedule of prime (KISIMA-Mad46 s.c.), boost (VSV-GP-Mad46 i.v. or KISIMA-Mad46 s.c.) and 2nd boost (KISIMA-Mad46 s.c.) vaccination after MC-38 tumor implantation in female C57BL/6 mice for monitoring tumor-growth and prolonged overall survival. (B) Individual tumor-growth curves in mm³ post-tumor implantation for untreated controls, KKK or KVK-treated female C57BL/6 mice. (C) Kaplan–Meier survival graphs of MC-38 tumor-bearing female C57BL/6 mice (n = 7 per group). (D) Representative FACS dot plots of blood-derived Adpgk, Reps1 and Rpl18-specific CD8+ T cells. From left to right: Control, KK or KV treatment group is shown on day 18 post-MC-38 tumor implantatio (E) From left to right: % (upper part) or absolute numbers (lower part) of blood-derived Adpgk-, Reps1-, Rpl18- or all three (sum) antigen-specific CD8+ T cells sampled on day 16 or 17 post-MC-38 tumor implantation. Data in (D,E) are shown as means (grey bar) and derived from two independent experiments. * p < 0.05, *** p < 0.001, **** p < 0.0001 One-Way ANOVA followed by Tukey’s multiple comparison test. Data shown in (B,C) are derived from one experiment (n = 7). * p < 0.05 Mantel-Cox Log-rank test.